Preclinical antitumor efficacy evaluation of dendrimer-based methotrexate conjugatesMyc, Andrzej; Douce, Thomas B.; Ahuja, Niharika; Kotlyar, Alina; Kukowska-Latallo, Jolanta; Thomas, Thommey P.; Baker, James R. JrAnti-Cancer Drugs: February 2008 - Volume 19 - Issue 2 - p 143-149 doi: 10.1097/CAD.0b013e3282f28842 PRECLINICAL REPORTS Abstract Author InformationAuthors Article MetricsMetrics Our previous studies have demonstrated the in-vitro and in-vivo targeting of a generation-5 (G5) dendrimer-based multifunctional conjugate, which used folic acid (FA) as the targeting agent and methotrexate (MTX) as the chemotherapeutic drug. For the synthesized G5-FA-MTX nanodevice conjugate to be clinically applicable as a cancer therapeutic drug, it is important that the compound elicits cytotoxicity specifically and consistently. The aim of this work was to evaluate four independently synthesized batches of G5-FA-MTX conjugates for their cytotoxic potential and specificity. For determination of specificity, we have used a unique ‘coculture’ assay in which FA receptor-positive and FA receptor-negative cells were cultured together and have examined the preferential killing of the former. The results of our study show the batch-to-batch consistency and specificity of the G5-FA-MTX nanodevice in the preferential killing of FA receptor-positive cells. The coculture assay shows the consistency of the four different G5-FA-MTX conjugate lots in the specific killing of targeted cells. Further in-vivo studies are, however, necessary to prove the clinical potential of this targeted therapeutic nanodevice. Michigan Nanotechnology Institute for Medicine and Biological Sciences, University of Michigan Medical School, BSRB, Ann Arbor, Michigan, USA Correspondence to Research Assistant Professor Andrzej Myc, PhD, MNIMBS, Rm 4039, BSRB, University of Michigan, Ann Arbor, MI 48109, USA Tel: +1 734 615 1569; fax: +1 734 615 2506; e-mail: firstname.lastname@example.org Received 1 June 2007 Revised form accepted 22 September 2007 © 2008 Lippincott Williams & Wilkins, Inc.